Parkinson's disease: Biology and aetiology

Current Opinion in Neurology

Volumn 9, Issue 4, 1996, Pages 303-307

  Temlett, James A ^a  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

FREE RADICAL; GROWTH FACTOR; NEUROTRANSMITTER; NEUROTROPHIC FACTOR; PEPTIDE;

APOPTOSIS; CELL DEATH; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; GLIA CELL; HUMAN; MITOCHONDRIAL RESPIRATION; NEOSTRIATUM; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; SUBSTANTIA NIGRA;

EID: 0029743759     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199608000-00011     Document Type: Review

References (86)

1. Duvoisin RC, Golbe LI: Kindreds of dominantly inherited Parkinson's disease: keys to the riddle. Ann Neurol 1995, 38:355-356.
2. Ho SL, McCann KP, Bennett P, Kapadi AL, Waring RH, Ramsden DB, Wiliams AC: The molecular biology of xenobiotic enzymes and the predisposition to idiopathic Parkinson's disease. Adv Neurol 1996, 69:53-60. Complex molecular pathogenesis suggesting slow metabolism of sulphur compounds or biogenic amines, by hepatic P450 cytochrome systems, may allow a toxin to damage cells in a genetically vulnerable host.
3. Ruberg M, Scherman D, Javoyagid F, Agid Y: Dopamine denervation, age of onset and Parkinson's disease. Neurology 1995, 45:392.
4. Ahlskog JE, Uitti RJ, Low PA, Tyce GM, Nickander KK, Peterson RC, Kokmen E: No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Mov Disord 1995, 10:566-573.
5. Schapira AHV: Neurotoxicity and the mechanism of cell death in Parkinson's disease. Adv Neurol 1996, 69:161-165. The author summarizes current thought relevant to dopamine cell neurotoxicity, focusing on mitochondrial respiratory dysfunction.
6. Brooks DJ: Parkinson's disease - a single clinical entity? [Review]. Q J Med 1995, 88:81-91.
7. McKeith IG, Fairbairn AF, Perry RH, Thompson P: The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT). Br J Psychiatry 1994, 165:324-332.
8. Gouiderkhouja N, Vidailhet M, Bonnet AM, Pichon J, Agid Y: Pure striatonigral degeneration and Parkinson's disease: a comparative clinical study. Mov Disord 1995, 10:288-294.
9. Perry EK, Morns CM, Court JA, Cheng A, Fairbairn AF, McKeith IG, Irving D, Brown A, Perry RH: Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 1995, 64:385-395.
10. Comford ME, Chang L, Miller BL: The neuropathology of parkinsonism: an overview. Brain Cogn 1995, 28:321-341.
11. Braak H, Braak E, Yilmazer D, Devos RAJ, Jansen ENH, Bohl J, Jellinger K: Amygdala pathology in Parkinson's disease. Acta Neuropathol (Berl) 1994, 88:493-500.
12. Pillon B, Gouider-Kjouja N, Deweer B, Vidaihet M, Malapani C, Dubois B, Agid Y: Neuropsychological pattern of striatonigral degeneration: comparison with Parkinson's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1995, 58:174-179.
13. Varastet M, Riche D, Maziere M, Hantraye P: Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Neuroscience 1994, 63:47-56.
14. Perez-Otano I, Luquin MR, Oset C, Herrero MT, Kupsch A, Oertel W, Obeso JA, Del Rio J: Neurotoxicity induced by prenatal exposure to MPTP on the monoaminergic and peptidergic systems of the marmoset brain. Exp Neurol 1995, 131:108-113.
15. Bing G, Zhang Y, Watanabe Y, McEwen BS, Stone EA: Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res 1994, 668:261-265.
16. Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, Schapira AHV: Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994, 36:876-881.
17. Cooper JM, Daniel SE, Marsden CD, Schapira AHV: L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain. Mov Disord 1995, 10:295-297.
18. Przedborski S, Jacksonlewis V, Fahn S: Antiparkinsonian therapies and brain mitochondrial complex I. Mov Disord 1995, 10:312-317.
19. Cohen G: The brain on fire? [Editorial]. Ann Neurol 1994, 36:333-334.
20. Bandmann O, Davis MB, Marsden CD, Harding AE: Sequence of the superoxide dismutase 1 (SOD1) gene in familial Parkinson's disease. J Neurol Neurosurg Psychiatry 1995, 59:90-91.
21. Nishiyama K, Murayama S, Shimizu J, Ohya Y, Kwak S, Asayama K, Kanazawa I: Cu/Zn Superoxide dismutase-like immunoreactivity is present in Lewy bodies from Parkinson's disease: a light and electron microscopic immunocytochemical study. Neuropathol (Berl) 1995, 89:471-474.
22. Gelman BB: Iron in CNS disease. J Neuropathol Exp Neurol 1995, 54:477-486.
23. Loeffler DA, Connor JR, Juneau PL, Snyder BS, Kanaley L, Demaggio AJ, Nguyen H, Brickman CM, Lewin PA: Transferrin and iron in normal. Alzheimer's disease and Parkinson's disease brain regions. J Neurochem 1995, 65:710-716.
24. Sastry S, Arendash GW: Time-dependent changes in iron levels and associated neuronal loss within the substantia nigra following lesions within the neostriatum/globus pallidus complex. Neuroscience 1995, 67:649-666.
25. Yamada Y, Horisberger MA, Kawaguchi N, Moroo I, Toyoda T: Immunohistochemistry using antibodies to alpha-interferon and its induced protein, MxA, in Alzheimer's and Parkinson's disease brain tissues. Neurosci Lett 1994, 181:61-64.
26. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA: Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995, 45:1138-1143.
27. Gerlach M, Trautwein AX, Zecca L, Youdin MBH, Riederer P: Mossbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. Neurochemistry 1995, 65:923-926.
28. Sengstock GJ, Olanow CW, Dunn AJ, Barone S, Arendash W: Striatal dopaminergic markers, nigral volumes, and rotational behaviour following iron infusion into the rat substantia nigra. Exp Neurol 1994, 130:82-94.
29. Nielsen JE, Jensen LN, Krabbe J: Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. J Neurol Neurosurg Psychiatry 1995, 59:318-321.
30. Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, Shults CW: Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995, 37:714-722.
31. Finnegan KT, Irwin I, Delanney LE, Langston JW: Age-dependent effects of the 2′-methyl analog of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: prevention by inhibitors of monoamine oxidase B. J Pharmacol Exp Ther 1995, 273:716-720.
32. Maruyama W, Dostert P, Naoi M: Dopamine-derived 1-methyl-6,7-dihydroxyisoquinolines as hydroxyl radical promoters and scavengers in the rat brain: in vivo and in vitro studies. Neurochemistry 1995, 64:2635-2643.
33. Tohgi H, Abe T, Saheki M, Hamato F, Sasaki K, Takahashi S: Reduced and oxidized forms of glutathione and alpha-tocopherol in the cerebrospinal fluid of parkinsonian patients: comparison between, before and after L-dopa treatment. Neurosci Lett 1995, 184:21-24.
34. Koutsilieri E, Ocallaghan JFX, Chen TS, Riederer P, Rausch WD: Selegiline enhances survival and neurite outgrowth of MPP(+)-reated dopaminergic neurons. Eur J Pharmacol 1994, 269:R3-R4.
35. Brannan T, Yahr MD: Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol 1995, 37:95-98.
36. Rowe PM: Topics for Parkinson's disease research identified. Lancet 1995, 8977:766.
37. Calne D: Selegiline in Parkinson's disease: no neuroprotective effect: increased mortality. BMJ 1995, 311:1583-1584.
38. Lees AJ and Parkinson's Disease Research Group (UK): Comparison of the therapeutic effects mortality data of levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995, 311:1602-1607.
39. Stern G: Parkinson's disease: the apoptosis hypothesis. Adv Neurol 1996, 69:101-107. A balanced discussion evaluating apoptotic mechanisms in neurodegeneration. Caution is shown in regard to the knowledge gap between understanding cell death, and the implications of toxic or genetic neurodegenerative diseases is stressed.
40. Walkinshaw G, Waters CM: Induction of apoptosis in catecholaminergic PC12 cells by L-dopa - implications for the treatment of Parkinson's disease. J Clin Invest 1995, 95:2458-2464.
41. Le WD, Engelhardt J, Xie WJ, Schneider L, Smith RG, Appel SH: Experimental autoimmune nigral damage in guinea pigs. Neuroimmunology 1995, 57:45-53.
42. 2 receptor mRNA-containing neurons: a quantitative nonradioactive in situ hybridization study. J Neurosci 1995, 15:1735-1740.
43. Huang CC, Lee EHY: Alteration of corticotrophin-releasing factor immunoreactivity in MPTP-treated rats. J Neurosci Res 1995, 41:471-480.
44. Wood KA, Youle RJ: The role of free radicals and p53 in neurone apoptosis in vivo. J Neurosci 1995, 15:5815-5857.
45. Chen SC, Curran T, Morgan JI: Apoptosis in the nervous system: new revelations. J Clin Path 1995, 48:7-12.
46. Drago J, Kilpatrick TJ, Koblar SA, Talman PS: Growth factors: potential therapeutic application in neurology. [Editorial]. J Neurol Neurosurg Psych 1994, 57:1445-1450.
47. Oppenheim RW, Houenou LJ, Johnson JE, Lin Leu-Fen F, Li L, Lo AC, Newsome AL, Prevette DM, Wang S: Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF. Nature 1995, 373:344-346.
48. Campbell K, Wictorin K, Bjorklund A: Neurotransmitter-related gene expression in intrastriatal striatal transplants. II. Characterization of efferent projecting graft neurons. Neuroscience 1995, 64:35-47.
49. Lindner MD, Winn SR, Baetge EE, Hammang JP, Gentile FT, Doherty E, McDermott PE, Frydel B, Ullman MD, Schallert T, Emerich DF: Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Exp Neurol 1995, 132:62-76.
50. Rosenstein JM: Why do neural transplants survive? An examination of some metabolic and pathophysiological considerations in neural transplantation. Exp Neurol 1995, 133:1-6.
51. Tomac A, Lindqvist E, Lin L-FH, Ogren SO, Young D, Hoffer BJ, Olsen L: Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373:335-339. GDNF promotes survival of cultured fetal mesencephalic dopamine cells in MPTP-lesioned mice. Both protection before MPTP was administered and reparation and limitation of cell damage following toxic exposure is shown.
52. Beck KD, Valverde J, Alexl T, Poulsen K, Moffat B, Vaudlen RA, Rosenthal A, Hefti F: Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995, 373:339-341. Rat recombinant GDNF promoted dopamine cell survival in hydroxydopamine-axotomized rats. Elegant experiments designed to test the trophic effects of GDNF.
53. Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, Hudson J, Martin D, Lin LFH, Gerhardt GA: Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994, 182:107-111.
54. Rosenstein JM: Why do transplants survive? [Commentary]. Exp Neurol 1995, 133:1-6.
55. Cheng H, Hoffer B, Stromberg I, Russel D, Oison L: The effect of glial cell line-derived neurotrophic factor in fibrin glue on developing dopamine neurons. Exp Brain Res 1995, 104:199-206.
56. Sauer H, Rosenblad C, Bjorklund A: Glial cell line-derived neurotrophic factor but not transforming growth factor β3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci U S A 1996, 92:8935-8939. An interesting paper showing human recombinant GDNF, but not transforming growth factor-β3, administered into the substantia nigra prevented dopamine cell atrophy and death following a neurotoxic lesion.
57. Yan Matheson C, Lopez OT: In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons. Nature 1995, 373:341-344.
58. Spenger C, Hyman C, Studer L, Egli M, Evtouchenko L, Jackson C, Dahl-Jorgensen A, Lindsay RM, Seiler RW: Effects of BDNF on dopaminergic, serotonergic and GABAergic neurons in cultures of human fetal ventral mesencephalon. Exp Neurol 1995, 133:50-63. The authors show recombinant human BDNF has beneficial effects in human fetal dopamine cell growth in organotypic culture but caution that BDNF is non-specific in that other cells also grow, differentiate and maintain cell viability.
59. Hoffer BJ, Hoffman A, Bowencamp K, Huettl P, Hudson J, Martin D, Lin L-F H, Gerhardt GA: Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994, 182:104-106.
60. Leu-Fen H, Doherty DH, Lile JD, Bektish S, Collins F: GDNF: a glial cell line neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
61. Schneider JS, Kean A, Distefano J: G(M1) ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice. J Neurosci Res 1995, 421:117-123.
62. Altar CA, Boylan CB, Fritsche M, Kackson C, Hyman C, Lindsay RM: The neurotrophins NT-4/5 and BDNF augment serotonin, dopamine, and GABAergic systems during behaviorally effective infusions to the substantia nigra. Exp Neurol 1994, 130:31-40.
63. + neurotoxicity against rat dopaminergic neurons in culture. Neuro Lett 1995, 193:53-56.
64. Othberg A, Odin P, Ballagi A, Ahgren A, Funa K, Lindvall O: Specific effects of platelet derived growth factor (PDGF) on fetal rat and human dopaminergic neurons in vitro. Exp Brain Res 1995, 105:111-122.
65. Mogi M, Hadara M, Kondo T, Reiderer P, Inagaki H, Minami M, Nagatsu T: Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Neurosci Lett 1994, 180:147-150.
66. Mena MA, Casjejos MJ, Gimenez-Gallego G, Garceade YJ: Fibroblast growth factors: structure-activity on dopamine neurons in vitro. J Neural Tsm 1995, 9:1-14.
67. Krewson CE, Klarman ML, Saltzman WM: Distribution of nerve growth factor direct delivery to brain interstitium. Brain Res 1995, 680:196-206.
68. Schneider JS, Roeltgen DP, Rothblat DS, Chapascrilly J, Seraydarian L, Rao J: GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy. J Neurol 1995, 45:1149-1154.
69. Graybiel AM: Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990, 13:224-253.
70. Gerfen CR: The neostriatal mosaic: multiple levels of compartmental organisation. Trends Neurosci 15:133-139.
71. Albin RI, Young AB, Penney JB: The functional anatomy of disorders of the basal ganglia. Trends Neurosci 1995, 18:63-64.
72. Graybiel AM: The basal ganglia. Trends Neurosci 1995, 18:60-62.
73. Parent A, Asselin M-C, Côté PY: Dopaminergic regulation of peptide gene expression in the striatum of normal and parkinsonian monkeys. Adv Neurol 1996, 69:73-77. This article examines dynorphin and enkephalin mRNA signals utilizing in-situ hybridization histochemistry in primates with MPTP-parkinsonism. The authors emphasise that the dorsal and rostral gradient differs from rodent models, suggesting dynorphin is uniformly decreased but enkephalin increased specifically in the striatal regions that integrates sensorimotor cortical input.
74. Surmeier JD, Kitai ST: Dopaminergic regulation of striatal efferent pathways. Curr Opin Neurobiol 1994, 4:915-919.
75. Gerfen CR, Keefe KA: Neostriatal dopamine receptors. Trends Neurosci 1994, 17:2-3.
76. Bloch B, Le Moine C: Neostriatal dopamine receptors. Trends Neurosci 1994, 17:3-5.
77. Kawaguchi Y, Wilson CJ, Augood SJ, Emson PC: Striatal interneurons: chemical, physiological and morphological characterization. Trends Neurosci 1995, 18:527-535. Beautifully delineated striatal interneurons immunocytochemically shown to interconnect and facilitate striatal pathways that station and transverse the striatum. The function and interregional variation of the striatum is yet to be fully worked out.
78. Campbell K, Wictorin K, Bjorklund A: Neurotransmitter-related gene expression in intrastriatal striatal transplant 1. Phenotypical characterization of striatal and non-striatal graft regions. Neuroscience 1995, 4:17-33.
79. Campbell K, Wictorin K, Bjorklund A: Neurotransmitter-related gene expression in intrastriatal striatal transplants. 2. Characterization of efferent projecting graft neurons. Neuroscience 1995, 64:35-47.
80. Isacson O: Behavioral effects and gene delivery in a rat model of Parkinson's disease. Science 1995, 269:5225-5226.
81. Soghomonian JJ, Pedneault S, Audet G, Parent A: Increased glutamate decarboxylase mRNA levels in the striatum and pallidum of MPTP-treated primates. J Neurosci 1994, 14:6256-6265.
82. Blanchard V, Chritin M, Vyas S, Savasta M, Feuerstein C, Agid Y, Javoyagid F, Raismanvozari R: Long-term induction of tyrosine hydroxylase expression: compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain. J Neurochem 1995, 4:1669-1679.
83. Anglade P, Tsuji S, Javoyagid F, Agid Y, Hirsch EC: Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease. Ann Neurol 1995, 37:265-272.
84. 2 receptor messenger RNAs are differentially expressed in limbic- and motor-related subpopulations of human mesencephalic neurons. Neuroscience 1994, 63:357-362.
85. Yamada M, Yamada M, Richelson E: Heterogeneity of melanized neurons expressing neurotensin receptor messenger RNA in the substantia nigra and the nucleus paranigralis of control and Parkinson's disease brain. Neuroscience 1995, 64:405-417.
86. Carlsson A: Towards a new understanding of dopamine receptors. Clin Neuropharmacol 1995, 18(suppl 1):S6-S13.